Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Osphena(R) (ospemifene) to U.S. FDA Seeking Approval for the Treatment of Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause

BLAINVILLE, QC, Oct. 23, 2018 -- (Healthcare Sales & Marketing Network) - Duchesnay Inc., a pharmaceutical company specializing in women's health, announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administ... Biopharmaceuticals, FDA Duchesnay, Osphena, ospemifene

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044459

Source: HSMN NewsFeed - October 23, 2018 Category: Pharmaceuticals Source Type: news